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Background: Primary distal renal tubular acidosis (dRTA) caused by mutations in the genes that codify for the
H + −ATPase pump subunits is a heterogeneous disease with a poor phenotype-genotype correlation. Up to now,
large cohorts of dRTA Tunisian patients have not been analyzed, and molecular defects may differ from those
described in other ethnicities. We aim to identify molecular defects present in the ATP6V1B1, ATP6V0A4 and SLC4A1
genes in a Tunisian cohort, according to the following algorithm: first, ATP6V1B1 gene analysis in dRTA patients with
sensorineural hearing loss (SNHL) or unknown hearing status. Afterwards, ATP6V0A4 gene study in dRTA patients
with normal hearing, and in those without any structural mutation in the ATP6V1B1 gene despite presenting SNHL.
Finally, analysis of the SLC4A1 gene in those patients with a negative result for the previous studies.
Methods: 25 children (19 boys) with dRTA from 20 families of Tunisian origin were studied. DNAs were extracted
by the standard phenol/chloroform method. Molecular analysis was performed by PCR amplification and direct
sequencing.
Results: In the index cases, ATP6V1B1 gene screening resulted in a mutation detection rate of 81.25%, which
increased up to 95% after ATP6V0A4 gene analysis. Three ATP6V1B1 mutations were observed: one frameshift
mutation (c.1155dupC; p.Ile386fs), in exon 12; a G to C single nucleotide substitution, on the acceptor splicing
site (c.175-1G > C; p.?) in intron 2, and one novel missense mutation (c.1102G > A; p.Glu368Lys), in exon 11. We
also report four mutations in the ATP6V0A4 gene: one single nucleotide deletion in exon 13 (c.1221delG; p.
Met408Cysfs*10); the nonsense c.16C > T; p.Arg6*, in exon 3; and the missense changes c.1739 T > C; p.Met580Thr,
in exon 17 and c.2035G > T; p.Asp679Tyr, in exon 19.
Conclusion: Molecular diagnosis of ATP6V1B1 and ATP6V0A4 genes was performed in a large Tunisian cohort with
dRTA. We identified three different ATP6V1B1 and four different ATP6V0A4 mutations in 25 Tunisian children. One of
them, c.1102G > A; p.Glu368Lys in the ATP6V1B1 gene, had not previously been described. Among deaf since
childhood patients, 75% had the ATP6V1B1 gene c.1155dupC mutation in homozygosis. Based on the results, we
propose a new diagnostic strategy to facilitate the genetic testing in North Africans with dRTA and SNHL.
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Distal renal tubular acidosis (dRTA) is defined by the in-
ability of the kidney to acidify urine, in presence of
metabolic acidosis [1,2]. Patients present with hyper-
chloraemic metabolic acidosis, hypokalaemia [3], bone
disease and, commonly, nephrocalcinosis. Some affected
individuals also exhibit hearing impairment [3,4]. Mal-
function of the H + −adenosine triphosphatase (ATPase)
pumps, or Cl/HCO3- (anion exchanger AE1) at the α-
intercalated cells of the distal nephron causes failure to
excrete acid or reabsorb bicarbonate, respectively, and
leads to primary dRTA [1,5].
Primary dRTA caused by mutations of H + −ATPase
pump subunits is wide genetic and clinically heteroge-
neous [6]. In 1999, Karet et al demonstrated that, in fam-
ilies with classic dRTA and early sensorineural hearing
loss (SNHL), which became clinically evident from birth
to late childhood, the disease was caused by mutations in
the ATP6V1B1 gene, encoding the B subunit of the H +
ATPase pump [7]. Later, in 2000, Smith et al found that
some families with dRTA and normal audiometry pre-
sented with mutations in the ATP6V0A4 gene, which en-
codes for the A4 subunit of the H +ATPase pump [8].
Despite those original molecular descriptions distin-
guished between ATP6V1B1 and ATP6V0A4 gene muta-
tions based on the presence or absence of early SNHL,
phenotype overlapping between both subgroups of pa-
tients makes that classification inaccurate. Indeed, Stover
et al demonstrated that young adult patients with
ATP6V0A4 mutations could develop mild SNHL in the
long term [9]. Further, some dRTA patients without
early SNHL were found to present mutations in the
ATP6V1B1 gene as well [10,11].
Further, autosomal dominant (AD) and autosomal re-
cessive (AR) dRTA have also been associated with muta-
tions in the SLC4A1 gene encoding the human AE1
[12-15], which also plays a central role in the main-
tenance of acid–base balance [16,17]. Overall, lack of
phenotype-genotype correlation supports the need of
genetic analysis in dRTA patients.
Up to now, small series of patients with dRTA from
different ethnic backgrounds had been genetically stu-
died [7-9,11,18]. Despite a few data on Tunisians have
been reported [8,9,11], to our knowledge large cohorts
of Tunisian patients with dRTA have not yet been ana-
lyzed. In order to establish the genetic diagnosis of pri-
mary dRTA in Tunisia, this study aimed to identify the
molecular defects that occur in ATP6V1B1, ATP6V0A4
and SLC4A1 genes using a proposed algorithm.
Methods
Patients
We studied 25 children (19 boys and 6 girls) from 20
unrelated families of Tunisian origin, who had beenclinically diagnosed of primary dRTA [19]. The study
group was recruited after deep review of every medical
record with the diagnosis of dRTA, and recall of those
affected subjects in four Tunisian hospitals: Hospital
Fattouma Bourguiba of Monastir (13 patients from 10
families), Hospital Ibn al-Jazzar of Kairouan (9 patients
from 7 families), Hospital Mohamed Ben Sassi of Gabes
(2 patients from 2 families), and Hospital Tahar Sfar of
Mahdia (one patient). After the four Medical Ethical
Committees belonging to the hospitals from which pa-
tients were recruited approved the project, and after in-
formed consent was given, we recorded patients’ data
regarding family history, symptoms, acid–base and bio-
chemistry at presentation, as well as kidney ultrasound.
Clinical diagnosis of dRTA was based on the simulta-
neous presence of non-gap metabolic acidosis (plasma
bicarbonate <20 mEq/L) and inability to reduce urinary
pH below 5.5 [20]. Additional features were dehydration,
failure to thrive, polyuria, and hypokalemia as described
[19]. Hearing was assessed by pure-tone audiometry and/
or auditory evoked responses, and the presence of SNHL
was graded according to the “Bureau International
d’Audiophonologie” recommendations (www.biap.org).
Moreover, 17 asymptomatic patients’ parents without
metabolic acidosis were also studied.
DNA analysis
Peripheral blood samples from the patients were collec-
ted on EDTA tubes. DNAs were extracted by the stand-
ard method of phenol/chloroform [21]. We planned to
optimize the study of the three genes described as
being responsible for primary dRTA (ATP6V1B1, OMIM
*192132; ATP6V0A4, OMIM *605239 and SLC4A1,
OMIM +109270) using the following algorithm: first, we
analyzed the ATP6V1B1 gene for those patients with
dRTA and SNHL or unknown hearing status. Afterwards,
we studied the ATP6V0A4 gene in those patients with
dRTA but normal hearing, and in those who were negative
for ATP6V1B1 gene mutation screening despite presence
of SNHL. Finally, we planned to investigate the SLC4A1
gene in those remaining patients with dRTA but no identi-
fied mutations in either ATP6V1B1 or ATP6V0A4 genes
(Figure 1).
We used previously reported primers [7] for the poly-
merase chain reaction (PCR) amplification of the exonic
and flanking intronic regions of the ATP6V1B1 gene.
Amplification was conducted for the coding regions and
flanking intronic sequences of ATP6V0A4 using a set of
newly designed primers pairs. Structural analysis of the
SLC4A1 gene was performed using both previously de-
scribed [22] and newly designed primers (for the amplifi-
cation of the three first exons). Two overlapping regions
in SLC4A1 gene intron 3 (one for the potential kidney
promoter and another for the possible 5’ sequence of the
Figure 1 Algorithm followed for the genetic analysis. 1, 2 and 3 (the different steps of the analysis).
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In all cases, primer sequences and PCR conditions are
available on request. Amplified products were purified
using ExoSap (USB, Cleveland, OH, USA) and sequenced
in both strands on an ABI3130xl Genetic Analyzer (Ap-
plied Biosystems, Foster City, CA, USA). Sequences were
analyzed with Sequencing Analysis software v.5.2 (Applied
Biosystems) and compared with the references se-
quences of each gene (Ensembl identifiers: ATP6V1B1:
ENSG00000116039, ATP6V0A4: ENSG00000105929
and SLC4A1: ENSG00000004939), using SeqScape soft-
ware v.2.5 (Applied Biosystems).
Mutation prediction
The potential pathogenic effect of novel missense muta-
tions was analyzed in silico using SIFT (http://sift.jcvi.
org/) and Polyphen-2 (http://genetics.bwh.harvard.edu/
pph2/) software packages, which are able to predict
whether an amino acid substitution may affect protein
function, based on sequence homology and physical
properties of substituted amino acids.
Results
dRTA kindreds
Twenty five Tunisian children (19 males) of 8 (0.6-20)
(median, range) years of age were diagnosed with pri-
mary dRTA at 6.27 (0.8-36) months of life. At diagnosis,
most relevant symptoms were feeding difficulties, de-
hydration, and failure to thrive (Table 1). One of thepatients (case 7.2) was asymptomatic at recruitment; he
was diagnosed by molecular familiar screening, as he
had an affected brother (case 7.1) and has developed the
symptoms later. All patients presented with a non-gap
metabolic acidosis (plasma pH 7.23 ± 0.15; bicarbonate
9.67 ± 0.62 mEq/L), and inability to renal acidification, as
shown by alkaline urine (urine pH 7 ± 0.67). Further,
common findings were hypokalemia (15 cases had K <
3.5 mEq/L), diffuse nephrocalcinosis which was demon-
strated in all but three children (nephrocalcinosis was
not observed in subjects 7.1 and 19.1 and ultrasound
data was not available in case 11.1), rickets (5 cases), and
total hearing loss/cophosis (16 cases). Unexpected
hyperkalemia was observed in a 1 month old patient
(case 13.1), possibly due to extreme acidosis and poten-
tial inadequate blood draw (Table 1). The disease was
inherited following an AR pattern, and remarkably con-
sanguinity rate was very high in the study group (80%)
(4 families in first degree of consanguinity, 5 families in
second degree, 3 families in third degree and 4 families
reported consanguinity in an unknown status).
Mutation detection
All molecular results are indicated in Table 2. Following
the strategy described above (Figure 1), we analyzed the
ATP6V1B1 gene in 16 index cases who presented dRTA
and SNHL (12 cases) or an unknown hearing status
(4 cases). Mutations were detected in homozygosis in 13
probands. Afterwards, we investigated the ATP6V0A4
Table 1 Clinical presentation of the 25 Tunisian children with dRTA
Case Symptoms Age at diagnosis
(months)






1.1 Vomits, growth failure 6 7.3 10.4 2.26 7 Yes
2.1 Vomits, growth failure 7 7.22 9.7 3 6.5 Yes
3.1 Growth failure 1.3 7.14 7 2.3 6 Yes
3.2 Speech delay, growth failure, rickets 36 7.21 12.3 2.7 7 Yes
4.1 Dehydration 1.3 7.21 10.4 4.1 6.5 Yes
5.1 Vomits, diarrhea, growth failure 3 7.3 6.9 4.06 7.5 Yes
5.2 Growth failure, dehydration 3.5 7.25 8.3 4.65 6 Yes
6.1 Growth failure, fever 3 7.34 12.4 3.82 7 Yes
7.1 Loss of weight, dehydration, fever, vomits,
diarrhea
4 7.29 12.1 2.43 6 No
7.2 Growth failure, dehydration, polyuria, urine
infection
11 7.17 8.5 2.9 7 Yes
8.1 Fever, vomits, growth failure 3.3 7.3 8.6 2.68 7 Yes
9.1 Vomits, dehydration, vitamin D-resistant rickets 1 7 NA 4.22 8 Yes
10.1 Vomits, dehydration, leukocyturia 3 7.3 11.4 2 7 Yes
10.2 Dehydration, vomits 6 7.4 14.5 3.2 6.5 Yes
11.1 Diarrhea, vomits, polyuria, rickets 16 7.32 11.6 3.12 NA NA
12.1 Vomits, dehydration, growth failure 5 7.28 NA 2.4 7.5 Yes
13.1 Vomits after each feeding 1 7.23 11.3 7.2 7 Yes
14.1 Dehydration, respiratory distress 0.8 7.1 3.4 2 8 Yes
15.1 Dehydration, vomits, feeding difficulties 1.5 7.19 8.4 3.5 7 Yes
16.1 Vomits, feeding difficulties, severe dehydration,
diarrhea, vitamin D-resistant rickets, severe
osteopenia
18 7.18 9.6 NA 7.5 Yes
16.2 Hypotonia, failure to thrive, severe vitamin
D-resistant rickets, inability to walk, dumb
17 7.15 9.4 4.1 NA Yes
17.1 Vomits, dehydration, respiratory infection,
breathing difficulties
0.9 7.29 12.5 3.11 8 Yes
18.1 Dehydration, vomits, polyuria 2 7.15 6.1 3.9 7 Yes
19.1 Bronchiolitis and cough 3 7.13 8.8 3.8 8 No
20.1 Dehydration, axial hypotonia, hypotrophy 2.3 7.39 9 2.2 8 Yes
6.27 (0.8–36)* 7.23 ± 0.15** 9.67 ± 0.62** 3.3 ± 0.83** 7 ± 0.67**
*** (mEq/L) 7.35-7.45 22-28 3.5-5 5.5-6.5
Abbreviations: P (plasma), U (urine), NA (not available). *:median (range); **:mean value ± SD; ***:normal ranges.
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mutations, and in those 4 index cases with no hearing
loss. Mutations were detected in all 7 probands, 5 of
them in homozygosis (4 with normal hearing and 1 with
unknown hearing status) and two in heterozygosis, in
which loss of hearing was present in one case and the
other had an unknown hearing status. Further, in those
two patients with isolated heterozygous ATP6V0A4 gene
mutations, we screened for the second mutations in the
SLC4A1 gene, in order to complete the genetic diagnosis
of all known causative genes of primary dRTA. We did
not find any SLC4A1 gene mutation, and therefore, thesecond mutation in those two siblings, if present, re-
mained unidentified.
On the basis of this genetic diagnosis strategy in pa-
tients with dRTA, which is based on the presence of
SNHL, the initial ATP6V1B1 gene screening resulted in
a mutation detection rate of 81.25% (26/32 alleles). After
ATP6V0A4 gene analysis, the mutation detection rate in-
creased up to 95% of the probands (38/40 alleles). That
diagnostic approach was reinforced by the fact that no
phenotypic difference, apart from the presence or ab-
sence of hearing impairment, was observed between pa-
tients with ATP6V1B1 vs. ATP6V0A4 mutations in the
Table 2 Genetic results of the 25 Tunisian patients with dRTA, according to family history and presence of
sensorineural hearing loss (SNHL)
Case Origin Consanguinity SNHL Gene Mutation Protein
1.1 Monastir Yes Yes ATP6V1B1 c.175-1G > C p.?
2.1 Monastir Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
3.1 Monastir Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
3.2 Monastir Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
4.1 Monastir Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
5.1 Monastir Yes NA ATP6V1B1 c.1102G > A p.Glu368Lys (p.E368K)
5.2 Monastir Yes Yes ATP6V1B1 c.1102G > A p.Glu368Lys (p.E368K)
6.1 Monastir No Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
7.1 Monastir Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
7.2 Monastir Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
8.1 Monastir Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
9.1 Kairouan No NA ATP6V1B1 c.175-1G > C p.?
10.1 Kairouan Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
10.2 Kairouan Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
11.1 Kairouan Yes NA ATP6V1B1 c.175-1G > C p.?
12.1 Gabes No Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
13.1 Gabes Yes Yes ATP6V1B1 c.1155dupC p.Ile386Hisfs*56 (p.I386Hfs*56)
14.1 Mahdia Yes No ATP6V0A4 c.1221delG p.Met408Cysfs*10 (p.M408Cfs*10)
15.1 Kairouan Yes NA ATP6V0A4 c.16C > T p.Arg6* (p.R6*)
16.1 Kairouan Yes Yes ATP6V0A4 c.2035G > T p.Asp679Tyr (p.D679Y) heterozygous
16.2 Kairouan Yes Yes ATP6V0A4 c.2035G > T p.Asp679Tyr (p.D679Y) heterozygous
17.1 Kairouan Yes No ATP6V0A4 c.16C > T p.Arg6* (p.R6*)
18.1 Monastir Yes No ATP6V0A4 c.16C > T p.Arg6* (p.R6*)
19.1 Monastir No NA ATP6V0A4 c.1739 T > C p.Met580Thr (p.M580T) heterozygous
20.1 Kairouan Yes No ATP6V0A4 c.16C > T p.Arg6* (p.R6*)
Otherwise stated, mutations are present in homozygosis.
cDNA and protein numbering according to Ensembl identifiers: ATP6V1B1: ENSG00000116039, and ATP6V0A4: ENSG00000105929.
Abbreviations: SNHL (sensorineural hearing loss), NA (Not available).
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study were distributed throughout both ATP6V1B1
and ATP6V0A4 genes (Figure 2), so no hot-spot was
identified in any of the genes.
Mutations in the ATP6V1B1 gene
Analysis of the coding regions and flanking intronic
sequences of the ATP6V1B1 gene showed the pre-
sence of three different mutations in 13 families
(Table 2). One of them was a missense mutation (c.1102G
>A; p.Glu368Lys), another was a frameshift mutation
(c.1155dupC; p.Ile386fs), and the third was a splice-site
mutation (c.175-1G > C; p.?). The first one had not yet
been described.
The novel missense mutation in exon 11 (c.1102G > A;
p.Glu368Lys) was identified in two siblings (cases 5.1,
5.2) in the current study. That guanine to adenine substi-
tution leads to the change of the amino acid glutamine tolysine. We did not perform a functional analysis of the
mutated protein, but a molecular difference between these
two residues (glutamic acid is an acidic amino acid,
whereas lysine is a basic one) supports the hypothesis that
this replacement may affect the structure of the protein
subunit, thus the function, folding, or trafficking of that
protein. Indeed, glutamic acid in position 368 remains
highly conserved among species in proton ATPases. Data
obtained using SIFT and Polyphen-2 bioinformatics soft-
ware provided additional support for the pathogenic effect
of this mutation. Furthermore, we did not find this muta-
tion in 110 Tunisian healthy subjects.
Remarkably, the c.1155dupC mutation was observed
in homozygosis in 12 patients from 9 families (cases 2.1,
3.1, 3.2, 4.1, 6.1, 7.1, 7.2, 8.1, 10.1, 10.2, 12.1 and 13.1).
In 11 of these 12 patients, SNHL was evident since
childhood, but in one of them with normal hearing ca-
pability at diagnosis (case 7.2, diagnosed by molecular
5’ UTR
1 2 3 4 6 7 11 12 13 145 8 9 10
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Figure 2 Schematic representation of the ATP6V1B1 (A) and the ATP6V0A4 (B) genes with the localization of the mutations found in
this study. *: Novel mutation. “Heterozygous.
Elhayek et al. BMC Medical Genetics 2013, 14:119 Page 6 of 10
http://www.biomedcentral.com/1471-2350/14/119familiar screening), hypoacusia appeared later. This
frameshift mutation results in the generation of a pre-
mature stop codon after a short segment from the
generated novel triplet. Parents of the siblings 10.1,
10.2, 12.1 and 13.1 were heterozygous, thus carriers
for that mutation. The other parents’ samples were
not available for genetic testing.
Another mutation in intron 2, affecting the splice ac-
ceptor site (c.175-1G > C; p.?), was identified in three
probands (1.1, 9.1 and 11.1) from three different families.
Mother of 9.1 (father’s sample was not available) and
both parents of 11.1 were found to be heterozygous for
this mutation. This mutation predicts the loss of the ac-
ceptor splice site [11].
In addition, we found a novel heterozygous poly-
morphic change in intron 5 (c.368-27 C > T) in four pa-
tients from four unrelated families (cases 1.1, 8.1, 11.1
and 14.1).
Mutations in the ATP6V0A4 gene
Screening for ATP6V0A4 mutations in 7 probands
(patients 14.1, 15.1, 16.1, 17.1, 18.1, 19.1 and 20.1)
showed the presence of four different mutations in
these 7 families (Table 2): two missense (c.1739 T > C;
p.Met580Thr in exon 17 and c.2035G > T; p.Asp679Tyr in
exon 19), one nonsense (c.16C > T; p.Arg6* in exon 3) and
one frameshift (c.1221delG; p.Met408Cysfs*10 in exon
13). The latter is a single-base deletion leading to a prema-
ture stop codon, predicting the consequent synthesis of a
truncated protein, lacking all the trans-membrane do-
mains. This mutation found in our series (case 14.1) has
previously been published as a case report [23]. Patient’s
mother was found to be heterozygous, thus carrier for the
mutation (father’s sample was not available).The missense c.2035G > T mutation was found in two
siblings (cases 16.1 and 16.2) in heterozygosis (their
father was also heterozygous for this mutation). It leads
to the change of aspartic acid in position 679 by tyrosine
[11]. In this family, we were not able to find the second
mutation responsible for recessive dRTA.
The second missense c.1739 T > C mutation was found
in one proband (case 15.1) in heterozygosis. This muta-
tion was described to be located in a predicted trans-
membrane segment [8]. The substitution of methionine
in position 580 by threonine is likely to disrupt secon-
dary structure, function or both.
The nonsense c.16C > T mutation was identified in
four families (cases 15.1, 17.1, 18.1 and 20.1). It causes
the substitution of Arg6 by a premature stop codon. Pre-
diction analysis showed that this nonsense mutation
should lead to an abnormally short protein of only 6
amino acids (p.Arg6*). Further, mother of 17.1, father of
18.1 and both parents of 20.1 were found to be heterozy-
gous for the mutation.
In addition, we found three polymorphic changes in
both heterozygosis or homozygosis: (c.5 T > C; p.Val2Ala)
in exon 3 in 7 patients (14.1, 15.1, 16.2, 17.1, 18.1, 19.1
and 20.1), c.1662C > T; p.Phe554Phe in exon 16 in three
patients (16.1, 16.2 and 19.1) and c.1812 T > C; p.
His604His in exon 17 in 8 patients (14.1, 15.1, 16.1, 16.2,
17.1, 18.1, 19.1 and 20.1).
Discussion
This current study is, to our knowledge, the first large
Tunisian dRTA cohort that has been genetically stu-
died so far. As a whole, we identified three different
ATP6V1B1 gene mutations (in 13 families), and four
ATP6V0A4 mutations (in 7 families) in 25 Tunisian
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served, c.1102G > A; p.Glu368Lys in the ATP6V1B1
gene. On the other hand, most studied patients were
deaf since early childhood and, remarkably, 75% of
them (12/16) had the ATP6V1B1 gene c.1155dupC muta-
tion [7] in homozygosis, a finding that may improve ge-
netic diagnosis in Tunisia and close populations.
Despite primary dRTA is a rare disease of unknown
prevalence, we found a surprising large number of af-
fected Tunisian patients, a country with an estimated
population of 10,4 million inhabitants and a mean en-
dogamy rate of 26% [24]. This can be explained, almost
in part, by the high rate of consanguinity found in our
study cohort, up to 80%. Patients’ clinical presentation
was consistent with the prototypic picture of primary
dRTA, and every patient showed inability to acidify urine
in presence of non-gap metabolic acidosis [1,3,19]. In
our series, ATP6V1B1 gene causative mutations were 2
time-fold more frequent than ATP6V0A4 gene muta-
tions: 13 vs. 7. This finding may be related not only to
ethnicity or the studied population’s characteristics, but
also to an easier recognizable pattern of severe acidosis
associated with early onset SNHL, leading straightfor-
ward to the disease clinical diagnosis [1,7].
Similar presentation with early onset of non-gap meta-
bolic acidosis, hypokalemia and nephrocalcinosis was
observed in almost all patients despite carrying different
mutations. No phenotype-genotype correlation in dRTA
with SNHL was detected in this cohort, as previously de-
scribed [10]. On the other hand, this study confirms the
association between ATP6V1B1 mutations and dRTA
with early onset SNHL since childhood, and ATP6V0A4
mutations with dRTA but normal hearing (at least until
young adulthood), as reported in the original disease
genetic descriptions [7,8,18,25,26], but conflicts with
some other reports [9,11], which described ATP6V0A4
gene mutations to be more frequent than ATP6V1B1
ones.
However, with more recent clinical follow up data, we
have become aware that hearing impairment may repre-
sent a spectrum in dRTA, and hearing loss may also de-
velop at an older age in a number of those affected
patients with ATP6V0A4 mutations, but likely less severe
than in those with ATP6V1B1 mutations [9]. Indeed,
two siblings (cases 16.1 and 16.2) carrying ATP6V0A4
mutations had dRTA with SNHL since childhood, as de-
scribed [11]. Reversely, patients with ATP6V1B1 muta-
tions may not present hearing loss [11]. One of our
patients with the ATP6V1B1 gene c.1155dupC mutation
(case 7.2) developed hypoacusia after diagnosis. In gen-
eral, these findings raise the question regarding po-
tential mechanisms involved in the effect of different
subunit mutations of the same proton pump over hearing
ability [9].Importantly, one of the most interesting findings of
this study was the detection of ATP6V1B1 c.1155dupC
mutation in homozygosis in 12 patients from 9 families.
In all probands, SNHL was evident since childhood, as
classically described [7]. This mutation is present in 12
out of 16 (75%) patients with SNHL. This c.1155dupC
mutation had previously been described in 12 families,
of which 7 are from North Africa [7,9,19]. Therefore, if
we consider these studies, performed in North African
patients with dRTA , it turns out that approximately
55% of patients suffering from dRTA with early onset
SNHL (before 4 years of age) carry this mutation.
On the basis of similar patients’ geographic origin, it
could be hypothesized that there might be a founder ef-
fect for the frameshift c.1155dupC mutation (Table 3).
Nevertheless, a previous study [11] performed in six
families with the recurrent p.Ile386fs mutation found they
presented with different haplotypes at the ATP6V1B1
locus, concluding that a founder effect was not the cause
of the high prevalence of this mutation in their popula-
tion. Unfortunately, we could not study ATP6V1B1 haplo-
types in our cohort due to the lack of available relatives,
but we plan to test this issue in the future. It is also pos-
sible that Ile386 appears as a potential “mutation hotspot”
due to a string of seven cytosine residues at the surroun-
ding positions, suggesting a DNA polymerase slippage
during replication.
Anyhow, this finding may facilitate and help for rapid
genetic diagnosis of dRTA in North African patients;
and therefore, we propose that in patients with dRTA
and SNHL from Northern Africa countries, c.1155dupC
mutation in the ATP6V1B1 gene should be screened first
and, then, analysis should continue with additional mu-
tation screening only in those affected subjects in whom
c.1155dupC is not found.
Regarding the origin of the other mutations, the
splice-site (c.175-1G > C; p.?) defect was described for
the first time in three families from Algeria and Tunisia
[11]. The nonsense c.16C > T mutation was previously
described in a Pakistani family [11]. The two missense
c.2035G > T and c.1739 T > C mutations were previously
described in one Pakistani [11] and one Turkish family
[8], respectively (Table 3).
On the other hand, the newly identified mutation
(c.1102G > A; p.Glu368Lys) may provide in the future
some insights into A1 subunit structure and function,
which are presently unknown in mammals.
The diagnostic strategy based on the presence of SNHL
was successfully used in the current study to determine
which gene to test first. Vargas-Poussou et al performed
linkage studies to identify the disease locus in consangui-
neous families, and then used the age of onset of SNHL to
determine which gene to test first in the non-consanguin-
eous families [11]. Comparing with the algorithm followed
Table 3 Geographic distribution of previously reported dRTA populations carrying the ATP6V1B1 and ATP6V0A4 gene
mutations described in this study
Gene Mutation Origin Number of families Reference
ATP6V1B1 c.1155dupC Sweden 1 [7]
Spain 2





Tunisia 9 Current study
c.175-1G > C Tunisia 1 [11]
Algeria 2
Tunisia 3 Current study
c.1102G > A Tunisia 1 Current study
ATP6V0A4 c.16C > T Pakistan 1 [11]
Tunisia 4 Current study
c.1739 T > C Turkey 1 [8]
Tunisia 1 Current study
c.2035G > T Pakistan 1 [11]
Tunisia 1 Current study
c.1221delG Tunisia 1 Current study and [23]
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tion detection global rate: 95% versus 79.5%.
Nevertheless, our mutation screening partially failed in
three patients (two of them are siblings). We only identi-
fied two already described heterozygous mutations
(c.2035G > T and c.1739 T > C) in the ATP6V0A4 gene.
We were unable to find the second mutation responsible
for the recessive inheritance of the disease, as described
by other authors [11], even after screening the SLC4A1
gene [12,27,28]. We admit that SLC4A1 gene was a poor
candidate for screening as our patients presented severe
metabolic acidosis early in life, but we wanted to exclude
the possibility of presenting any mutation in the SLC4A1
gene, as compound heterozygosity has been described
[14,29]. Anyway, we cannot rule out the possibility of a
potential undetected deletion involving one or more
exons of the analyzed genes [30]. Other authors have hy-
pothesized about the possibility of mutations occurring
in an unknown regulatory element of either gene, like
promoters [31] or that some intronic variants, especially
those affecting the normal splicing sites, may also be in-
volved in the pathogenesis of dRTA [11]. More plausible,
there might be other genes involved in tubular acidifica-
tion ability not yet discovered. Haplotype linkage studies
should be performed in those affected patients in whom
the second mutation is missed and we plan to continue
with that project in the future.Conclusion
In this report, the genetic analysis of a Tunisian cohort
of dRTA patients as well as a new diagnostic strategy to
facilitate the genetic testing in North Africans with
dRTA and SNHL is presented. The putative dRTA muta-
tion was found in 90% of the index cases (18/20, the
other two being heterozygous), thus genetically confir-
ming the clinical diagnosis.
Our findings confirm the association of ATP6V1B1 mu-
tations and early onset severe SNHL since childhood, and
identify delayed hearing loss as a feature associated with
ATP6V0A4 mutations in some patients as well. Based on
our results, we propose that in patients of Northern Africa
origin with dRTA and SNHL, c.1155dupC mutation in the
ATP6V1B1 gene should be screened first. Further studies
with more patients would be needed to confirm this result.
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